The company's financial leverage has increased as total debt rose to $48.5M in 2026Q1, while the current ratio compressed to 5.21 from a peak of 7.40 in 2025Q3.
| Total Current Assets | 245.87M | 256.42M | 237.17M | 226.5M | 226.72M | 133.65M | 158.43M | 128.06M | 97.16M | 69.56M | 20.83M | 22.47M | 27.51M |
| Cash & Short-Term Investments | 48.81M | 60.85M | 68.83M | 80.31M | 118.29M | 54.91M | 85.27M | 70.78M | 60.69M | 42.58M | 1.61M | 3.88M | 6.58M |
| Cash Only | 12.19M | 19.56M | 43.82M | 31.05M | 8.99M | 9.01M | 30.13M | 70.78M | 60.69M | 42.58M | 1.61M | 3.88M | 6.58M |
| Short-Term Investments | 36.62M | 41.3M | 25.01M | 49.25M | 109.3M | 45.9M | 55.14M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 54.43M | 53.84M | 42.36M | 34.62M | 24.8M | 17.94M | 17.55M | 16.57M | 9.5M | 5.6M | 4.1M | 3.82M | 2.77M |
| Days Sales Outstanding | 80.01 | 83.14 | 75.52 | 84.95 | 74.02 | 66.79 | 90.12 | 83.35 | 60.25 | 44.83 | 40.1 | 44.95 | 42.7 |
| Inventory | 134.02M | 133.79M | 117M | 105.85M | 78.19M | 57.57M | 52.99M | 38M | 25.71M | 20.55M | 14.89M | 14.55M | 17.33M |
| Days Inventory Outstanding | 726.94 | 766.77 | 760.87 | 1.03K | 902.34 | 852.58 | 1.21K | 773.43 | 630.65 | 671.35 | 497.06 | 566.96 | 892.69 |
| Other Current Assets | 8.61M | 7.94M | 1.96M | 5.72M | 1.47M | 3.23M | 2.62M | 1.25M | 0 | 831K | 233K | 0 | 577K |
| Total Non-Current Assets | 256.32M | 252.21M | 236.04M | 212.25M | 201.01M | 174.75M | 166.4M | 66.51M | 14.95M | 12.74M | 9.85M | 8.22M | 8.32M |
| Property, Plant & Equipment | 48.55M | 49.55M | 58.83M | 41.05M | 34.29M | 28.52M | 27.23M | 21.35M | 12.77M | 10.39M | 8.59M | 7.34M | 7.47M |
| Fixed Asset Turnover | 4.81x | 4.77x | 3.48x | 3.62x | 3.57x | 3.44x | 2.61x | 3.40x | 4.51x | 4.39x | 4.34x | 4.23x | 3.17x |
| Goodwill | 115.17M | 109.27M | 93.84M | 83.7M | 86.82M | 72.35M | 70.51M | 26.18M | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 63.8M | 77.71M | 81.18M | 84.56M | 79.9M | 69.76M | 64.25M | 18.97M | 2.18M | 2.35M | 1.26M | 887K | 852K |
| Long-Term Investments | 0 | 0 | 2.18M | 1.85M | 189.52M | 0 | 0 | 53.26M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 28.8M | 15.68M | 0 | 1.08M | -195.48M | 0 | 0 | -54.1M | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 502.19M | 508.63M | 473.21M | 438.75M | 427.73M | 308.4M | 324.83M | 194.56M | 112.11M | 82.3M | 30.68M | 30.69M | 35.83M |
| Asset Turnover | 0.48x | 0.46x | 0.43x | 0.34x | 0.29x | 0.32x | 0.22x | 0.37x | 0.51x | 0.55x | 1.22x | 1.01x | 0.66x |
| Asset Growth % | 32.04% | 7.49% | 7.86% | 2.58% | 38.69% | -5.06% | 66.95% | 73.56% | 36.21% | 168.29% | -0.05% | -14.34% | - |
| Total Current Liabilities | 47.18M | 46.2M | 33.96M | 41.67M | 30.87M | 29.71M | 35.03M | 13.66M | 9.22M | 9.47M | 7.25M | 6.34M | 3.22M |
| Accounts Payable | 19.7M | 18.79M | 8.91M | 12.65M | 11.15M | 9.32M | 10.04M | 6.47M | 3.97M | 5.5M | 3.54M | 2M | 645K |
| Days Payables Outstanding | 81.26 | 107.67 | 57.93 | 123.19 | 128.67 | 138.1 | 228.32 | 131.63 | 97.41 | 179.56 | 118.31 | 77.89 | 33.23 |
| Short-Term Debt | 172K | 170K | 160K | 152K | 144K | 13M | 12.36M | 124K | 118K | 113K | 107K | 101K | 97K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 5.95M | 0 | 0 | 4.35M | 3.55M | 2.9M | 2.22M | 2.26M | 1.48M |
| Other Current Liabilities | 27.31M | 16.64M | 8.89M | 7.39M | 6.88M | 2.04M | 8.09M | -1.63M | 1.58M | 954K | 1.38M | 1.98M | 992K |
| Current Ratio | 5.21x | 5.55x | 6.98x | 5.44x | 7.34x | 4.50x | 4.52x | 9.37x | 10.54x | 7.35x | 2.87x | 3.55x | 8.55x |
| Quick Ratio | 2.37x | 2.65x | 3.54x | 2.90x | 4.81x | 2.56x | 3.01x | 6.59x | 7.75x | 5.18x | 0.82x | 1.25x | 3.16x |
| Cash Conversion Cycle | 725.69 | 742.25 | 778.46 | 992.63 | 847.69 | 781.27 | 1.07K | 725.15 | 593.48 | 536.61 | 418.86 | 534.02 | 902.17 |
| Total Non-Current Liabilities | 69.11M | 115.84M | 84.68M | 20.05M | 18.21M | 53.32M | 55.03M | 38.54M | 21.16M | 25.34M | 17.43M | 13.04M | 14.63M |
| Long-Term Debt | 48.31M | 99.82M | 72.96M | 9.91M | 763K | 15.22M | 13.83M | 26.07M | 21.16M | 25.34M | 17.43M | 13.04M | 13.14M |
| Capital Lease Obligations | 0 | 0 | 5.66M | 0 | 0 | 293K | 323K | 63K | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 14.27M | 3.58M | 0 | 5.48M | 5.95M | 8.9M | 10.17M | -63K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 17.45M | 12.44M | 6.06M | 4.66M | 11.49M | 28.91M | 30.71M | 0 | 0 | 0 | 0 | 0 | 1.49M |
| Total Liabilities | 116.3M | 162.03M | 118.64M | 61.72M | 49.08M | 83.03M | 90.06M | 52.2M | 30.37M | 34.81M | 24.68M | 19.38M | 17.85M |
| Total Debt | 48.48M | 99.99M | 80.9M | 10.06M | 907K | 28.51M | 26.52M | 26.25M | 21.27M | 25.45M | 17.54M | 13.14M | 13.24M |
| Net Debt | 36.29M | 80.43M | 37.08M | -21M | -8.08M | 19.5M | -3.62M | -44.52M | -39.42M | -17.13M | 15.93M | 9.26M | 6.66M |
| Debt / Equity | 0.14x | 0.29x | 0.23x | 0.03x | 0.00x | 0.13x | 0.11x | 0.18x | 0.26x | 0.54x | 2.93x | 1.16x | 0.74x |
| Debt / EBITDA | -3.65x | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -2.73x | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -5.55x | -4.86x | -11.26x | - | -8.99x | -7.95x | -8.87x | -2.59x | -4.33x | -2.59x | -3.45x | -5.38x | -2.83x |
| Total Equity | 338.71M | 346.6M | 354.57M | 377.02M | 378.65M | 225.37M | 234.77M | 142.36M | 81.73M | 47.49M | 5.99M | 11.31M | 17.98M |
| Equity Growth % | -14.75% | -2.25% | -5.96% | -0.43% | 68.01% | -4% | 64.91% | 74.18% | 72.09% | 692.38% | -47.03% | -37.06% | - |
| Book Value per Share | 14.30 | 14.77 | 15.36 | 16.63 | 18.08 | 11.70 | 13.00 | 9.73 | 6.50 | 9.86 | 0.80 | 1.51 | 2.42 |
| Total Shareholders' Equity | 338.71M | 346.6M | 354.57M | 377.02M | 378.65M | 225.37M | 234.77M | 142.36M | 81.73M | 47.49M | 5.99M | 11.31M | 17.98M |
| Common Stock | 6K | 6K | 6K | 6K | 6K | 5K | 5K | 4K | 4K | 2K | 1K | 1K | 1K |
| Retained Earnings | -285.9M | -275.21M | -235.56M | -197.74M | -176.77M | -178.03M | -161.77M | -128.82M | -115.09M | -103.07M | -78.13M | -71.56M | -63.67M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.4M | -523K | -10.77M | -5.53M | -5.4M | 8.49M | 7.91M | -3K | -623K | 135K | 0 | -6.24M | -4.43M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liquidity and capital constraints
According to recent quarterly filings, OrthoPediatrics has seen its cash position dwindle from $44.6M in 2025Q2 to $12.2M by 2026Q1, signaling a weakening balance sheet trajectory as the company struggles to bridge the gap between its heavy capital intensity and its persistent net losses.
The consistent accumulation of retained earnings deficits, now totaling -$285.9M, underscores a long-term trend of value destruction that has not yet been offset by revenue growth. Investors should monitor whether the current trajectory of asset growth can be sustained without further dilutive equity raises or increased debt reliance.
As reported in financial statements, the company's debt load has increased significantly from $10.1M in 2023Q4 to $48.5M in 2026Q1, pushing the debt-to-equity ratio to 0.14 and suggesting a shift toward debt financing to support ongoing operations as internal cash generation remains elusive.
While the current leverage remains manageable in absolute terms, the rapid escalation in debt levels during a period of negative operating margins warrants caution. This reliance on debt may indicate that the company is exhausting its internal liquidity buffers and may face higher interest costs if refinancing becomes necessary.
Based on reported figures, the company's asset base is heavily weighted toward PPE and goodwill, with net PPE reaching $48.6M in 2026Q1, reflecting the significant upfront capital investment required to place surgical instrument sets in hospitals to drive future recurring revenue pull-through.
The high concentration of assets in specialized surgical kits creates a rigid cost structure that limits balance sheet flexibility. Because these assets are non-liquid and require ongoing maintenance, the company's ability to pivot its capital allocation strategy appears constrained by the necessity of supporting its existing installed base.
As indicated by the most recent quarterly data, the current ratio has compressed from a peak of 7.40 in 2025Q3 to 5.21 in 2026Q1, highlighting a tightening liquidity position that leaves the company with less of a buffer against unexpected shocks or prolonged operational cash burn.
While the current ratio remains technically healthy, the absolute decline in cash reserves is the more critical metric for investors to track. The company's reliance on cash to fund its growth initiatives suggests that liquidity could become a primary constraint if the current burn rate is not moderated.
Quick answers to the most common questions about buying KIDS stock.
As of 2025, OrthoPediatrics Corp. (KIDS) had total assets of $508.6M including $256.4M in current assets.
OrthoPediatrics Corp. (KIDS) carries total debt of $100.0M, offset by $60.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
OrthoPediatrics Corp. (KIDS) has total shareholders' equity (book value) of $346.6M ($14.77 book value per share). Book value represents the net worth of the company belonging to common stock holders.
OrthoPediatrics Corp. (KIDS) reported a current ratio of 5.55x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.